Cross-spectrum efficacy of spesolimab in IL-36-mediated dermatoses: a ′case study
Spesolimab produced rapid and durable control of IL-36-driven AGEP independent of IL36RN mutation status. These findings support IL-36 receptor blockade as a targeted therapeutic option for refractory AGEP and further position AGEP and GPP along a shared IL-36-mediated disease spectrum.
Authors
- ChangWen Ni
- Chaochao Chen (ORCID: https://orcid.org/0000-0003-1419-964X)
- Huang Ling (ORCID: https://orcid.org/0000-0002-3893-0612)
- RuoYan Tong
Institutions
- Dalian Medical University (CN)
- First Affiliated Hospital of Dalian Medical University (CN)
- Dali University (CN)
Publication Details
- Journal
- Journal of Dermatological Treatment
- Published
- 2025-11-24
- DOI
- https://doi.org/10.1080/09546634.2025.2586394
- Citations
- 1
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.80